Drug intelligence / Profile preview

RQ-2400

Development stage: Preclinical
Lead developer: RNAcure
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

RQ-2400 is an mRNA-based cancer immunotherapy being developed by RNAcure for the treatment of Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma. The therapeutic candidate is designed to deliver mRNA encoding specific EBV-related antigens into the patient's cells, prompting the expression of these viral proteins and subsequently triggering a robust, antigen-specific T-cell immune response against tumor cells. This approach aims to overcome the immune evasion mechanisms typically employed by EBV-positive malignancies. The program is currently in the early stages of development, utilizing RNAcure's proprietary mRNA and lipid nanoparticle (LNP) delivery platforms.

Beyond the preview

Go deeper on RQ-2400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RQ-2400.

Explore the full profile